Long term prognosis of ductal carcinoma with microinvasion: a retrospective cohort study.

Clicks: 439
ID: 81416
2018
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #2 of 9 articles by views in international journal of clinical and experimental pathology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Ductal carcinoma with microinvasion (DCIS-Mi) is an early-stage breast cancer with long-term behavior, prognosis and treatment not fully understood. The aim of our study was to explore the clinicopathological and prognostic features of DCIS-Mi with pure DCIS and IDC-T1 (invasive ductal carcinoma with a tumor size ≤2 cm) as control. We retrospectively reviewed 242 cases of DCIS-Mi, 280 cases of pure DCIS, and 347 cases of IDC-T1. The clinicopathological features, therapeutic schemes and survival status were compared among the three groups. After a median follow-up of 109 months, the 5-year disease-free survival (DFS) was lower for the DCIS-Mi patients than for the DCIS patients but higher than the IDC-T1 patients (100%, 96.89% and 87.86% respectively, <0.001). The 5-year breast cancer specific survival for DCIS-Mi patients was also between that of DCIS and IDC-T1 patients (100%, 99.32%, and 95.42% respectively, =0.001). Tumor size (<0.001, HR=18.31, 95% confidence interval (CI) 5.53-60.65) was identified as an independent prognostic factor for recurrence or metastasis. Furthermore, our study indicated that DCIS-Mi patients derived minimal, if any, benefit from chemotherapy treatment after mastectomy (=0.63, HR=1.50, 95% CI 0.29-7.87). To our knowledge, this is the largest follow-up cohort study on Chinese DCIS-Mi patients. Our data suggested that DCIS-Mi exhibited worse clinical outcome than pure DCIS but better than that of IDC-T1. Tumor size was an independent prognostic factor. Post-mastectomy chemotherapy did not help for increasing DFS for DCIS-Mi patients.
Reference Key
pu2018longinternational Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors
Journal international journal of clinical and experimental pathology
Year 2018
DOI
DOI not found
URL URL not found
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.